Stocks Comparison
Resmed vs Solventum: revenue, profit, margins and growth compared
Resmed brought in $5.7B of revenue in fiscal 2026, Solventum $8.3B in fiscal 2025. Revenue changed by +9.9% at Resmed and +0.9% at Solventum on the year before, so Resmed grew faster. Resmed kept 26.9% of its revenue as net profit, Solventum 18.7%. Free cash flow was $1.6B at Resmed and -$10M at Solventum.
Side by side, latest fiscal year
| RMD | SOLV | |
|---|---|---|
| Fiscal year ended | FY2026 (June 30, 2026) | FY2025 (December 31, 2025) |
| Revenue | $5.7B | $8.3B |
| Revenue growth | +9.9% | +0.9% |
| Net income | $1.5B | $1.6B |
| Net margin | 26.9% | 18.7% |
| Free cash flow | $1.6B | -$10M |
| Free cash flow margin | 29.2% | -0.1% |
| Earnings per share (diluted) | $10.43 | $8.88 |
| Cash | $1.5B | $878M |
| Debt | $399.4M | $5B |
| Price to earnings | 24.2 | 9.8 |
| Market value | $36.4B | $14.9B |
| Dividend yield | 0.95% | n/a |
| Rank by revenue in sector | #61 of 751 · Health care | #51 of 751 · Health care |
Over the years
Questions about Resmed and Solventum
Which is bigger by revenue, Resmed or Solventum?
Solventum is bigger by revenue: $8.3B in fiscal 2025, against $5.7B for Resmed in fiscal 2026.
Which keeps more of its revenue as profit, Resmed or Solventum?
Resmed had a net margin of 26.9% in fiscal 2026; Solventum had 18.7% in fiscal 2025.
Which grew revenue faster, Resmed or Solventum?
In their latest fiscal years revenue changed by +9.9% at Resmed and +0.9% at Solventum.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.